The guest on this week's nationally syndicated Motley Fool Money radio show is Ron Adner, an award-winning professor and author of the new book The Wide Lens: A New Strategy for Innovation. In the past decade, major pharmaceutical companies such as Eli Lilly, Pfizer, and MannKind were in a race to be the first to market an inhalable insulin. In this audio segment, Adner details how Pfizer did everything right, only to fail on a massive scale. Adner provides shareholders of pharmaceutical companies a key insight into what those companies need if they want to succeed in creating the next blockbuster drug.

Chris Hill owns shares of Pfizer. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.